BioFund Ventures manages the translational platforms, development programmes, and co-investment opportunities of BioFund — the portfolio behind the mission, built over years of focused, independent development.
Accessible, selectively, to partners who understand what they are joining.
BioFund's portfolio is designed as a coherent system — from computational discovery through engineering, screening, and parallel translational validation. The output is a de-risked candidate with a complete data package, ready for the next stage of development.
biodeep.ai generates high-confidence curative biologics candidates through AI-assisted protein design and de novo cell engineering. micronutri.ai identifies and optimizes preventive bioactive compounds targeting inflammation, immune dysregulation, and microbiome health — then enhances them through the proprietary UFP500 ultra-fine particle platform for superior bioavailability and biological efficacy.
Biologics candidates move to BioFund's cell engineering platform — producing a fully documented Master Cell Line Bank spanning biosimilar programmes, rare disease therapeutics, and emerging modalities. Each asset is built to late-stage development standards, with a complete data package supporting third-party validation and regulatory submission.
BioFund's proprietary 3D organoid platform uses patient-derived models to deliver rapid, high-fidelity go/no-go decisions across both curative biologics and preventive bioactives — in identical tissue contexts, with synergistic combination testing and exceptional predictive throughput. Built for internal use exclusively.
Promising candidates advance through parallel rodent and companion animal validation simultaneously. Companion animals naturally develop diseases that mirror human pathology — generating human-relevant regulatory data and veterinary clinical evidence within a single programme. This is the OneHealth methodology made operational.
De-risked candidates. Complete data packages. Ready for clinical development, regulatory strategy, and commercialization — on the partner's terms.
Research institutions and academic groups whose scientific work creates natural overlap with BioFund's platforms. Discovery Partners contribute intellectual access, publication credibility, and validated research insights — receiving in return a translational infrastructure that most academic programmes cannot build independently.
Organizations that bring complementary capability — intellectual property, clinical access, regulatory expertise, or manufacturing infrastructure. Contributing Partners accelerate specific programmes within the portfolio, structuring their involvement around the assets most relevant to their strategic position.
Family offices, foundations, and mission-aligned institutional investors who co-invest in specific programmes through project-specific vehicles. Each investment is bounded, purposeful, and structured around a single platform or development programme — never pooled across the broader portfolio.
BioFund Ventures structures co-investment through project-specific vehicles — aligned to individual platforms or programmes, not pooled across the portfolio. Each opportunity is designed for partners who bring more than capital: scientific credibility, strategic access, or operational capability that advances the mission.
Seven Families have built this over years of focused, independent development. They are prepared to share it — selectively — with those who understand what they are joining.
We respond only where there is genuine alignment with BioFund's mission and portfolio.